Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia Arjuna Roxb.Bark against PX- 407 induced hyperlipidemia

Department of Pharmacology, PSG College of Pharmacy, Coimbatore 641 004, India.
Indian journal of experimental biology (Impact Factor: 0.84). 04/2011; 49(4):282-8.
Source: PubMed

ABSTRACT The three fractions diethyl ether, ethyl acetate and ethanol. of T. arjuna exerted hypolipidemic and antioxidative effects at two different doses levels of 175 and 350 mg/kg body weight in Poloxamer (PX)-407 induced hyperlipidemic albino Wistar rats. The hypolipidemic and antioxidant effects of T. arjuna fractions were noticed as EtOH > diethyl ether > ethyl acetate. The results suggest that ethanolic fraction of T. arjuna possesses the potent properties of being antioxidant and hypolipidemic than other fractions. In turn, it has therapeutic potential for the prevention of coronary arterial disease.

Download full-text


Available from: Ramachandran Subramaniam, Sep 28, 2015
130 Reads
  • Source
    • "A number of clinical studies have also reported its beneficial effects in patients of chronic stable angina, endothelial dysfunction, heart failure and even ischemic mitral regurgitation[15]. Various extracts (water, hydroalcohol and alcohol) of the stem bark of T. arjuna and active compounds present in these extracts have been investigated in many experimental studies and has been reported to exhibit blood pressure (BP)-lowering effects[16], direct cardioprotective effects in terms of induction of myocardial heat shock protein[17], antioxidant activities[18], antiplatelet effects[19], hypolipidemic[20] and antiatherogenic effects[21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Terminalia arjuna Wight and Arn. (Combretaceae) is a tree having an extensive medicinal potential in cardiovascular disorders. Triterpenoids are mainly responsible for cardiovascular properties. Aqueous, hydroalcoholic and alcoholic extract of T. arjuna, arjunic acid and arjungenin were examined for their potential to inhibit CYP1A enzyme in rat and human liver microsomes. IC50 values of aqueous, hydroalcoholic and alcoholic extract of T. arjuna was found to be 11.4, 28.9 and 44.6 μg/ml in rat liver microsomes while 30.0, 29.7 and 39.0 μg/ml in human liver microsomes, respectively for CYP1A. However IC50 values of arjunic acid and arjungenin for both rat liver microsomes and human liver microsomes were found to be >50 μM. Arjunic acid and arjungenin did not show inhibition of CYP1A enzyme up to concentrations of 50 μM. These in vitro data indicate that Terminalia arjuna extracts contain constituents that can potently inhibit the activity of CYP1A, which could in turn lead to undesirable pharmacokinetic drug-herb interactions in vivo. Based on the in vitro data, interaction potential of the aqueous extract of Terminalia arjuna orally in rats was investigated. A probe substrate, phenacetin, was used to index the activity of CYP1A. In vivo pharmacokinetic study of coadministration of aqueous extract of Terminalia arjuna and phenacetin, revealed that the aqueous extract did not lead to any significant change in the pharmacokinetic parameters of phenacetin as compared with control group. Though there was no in vivo-in vitro correlation, drug interactions could arise with drugs having a narrow therapeutic range and extensively cleared by CYP1A enzyme, which could lead to undesirable side effects.
    Indian Journal of Pharmaceutical Sciences 03/2014; 76(2):138-47. · 0.48 Impact Factor
    • "Considering these factors, Terminalia Arjuna can potentially modulate all the three components of the disease. There are plethoras of clinical and experimental animal studies, which showed the role of Terminalia arjuna in CVD.[21, 22, 23] It has anti-inflammatory as well as immunomodulatory activity which could be the reason for improving the efficacy of Arogyavardhini Vati in this study. There are several components of Arogyavardhini Vati, which are known to have hypolipidemic effects, i.e., Picrorrhiza kurroa, Terminalia chebula, Terminalia bellerica, Emblica officinalis, and Guggulu.[24–29] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease has multifaceted in which dyslipidemia, inflammation, and immunity play an important role. Arjuna powder and Arogyavardhini Vati used for centuries has potential for combating these factors. Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) for dyslipidemia patients. Total of 108 patients were screened at CGHS Ayurvedic Hospital, New Delhi. Ninety-six patients satisfied inclusion criteria, and signed informed consent and detailed medical history was recorded. Arjuna powder (5 g, BD) for 3 weeks and then Arogyavardhini Vati (500 mg, BD) for 4 weeks were prescribed to the patients. The primary efficacy endpoint was reduction in serum total cholesterol, LDL, triglycerides, and increased HDL levels. Secondary endpoints included reduction in serum C-Reactive Protein (CRP) and blood glucose levels. Safety assessments included hepatic function (aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), bilirubin, and β(2) microglobulin), renal function (urea and creatinine and NGAL) tests, and urine mercury level. The study was completed by 87 patients. The male and female patients were 65.5% (57/87) and 34.5% (30/87), respectively. There was a significant reduction in total cholesterol, LDL, triglycerides, CRP, and blood glucose. However, raised HDL level was also observed. Safety assessment results showed no significant change in serum ALT, AST, ALP and bilirubin, urea, creatinine β(2) microglobulin, and NGAL levels at the end of study as compared to the baseline levels. In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) is safe and effective for dyslipidemia.
    04/2012; 33(2):197-201. DOI:10.4103/0974-8520.105238
  • [Show abstract] [Hide abstract]
    ABSTRACT: The bark of the tree Terminalia arjuna (Roxb.) is widely used in Indian medicine (Ayurveda) for various cardiovascular ailments. The bark has been reported to contain several bioactive compounds. Many experimental studies have reported its antioxidant, anti-ischemic, antihypertensive, and antihypertrophic effects, which have relevance to its therapeutic potential in cardiovascular diseases in humans. Several clinical studies have reported its efficacy mostly in patients with ischemic heart disease, hypertension, and heart failure. However, a major shortcoming in all these experimental and clinical studies is the absence of phytochemical standardization of the extracts. In addition, many clinical studies are poor in terms of design and methods used for generating safety data. This review discusses how to address all these issues for a scientific validation of this medicinal plant.
    American Journal of Cardiovascular Drugs 06/2012; 12(3):157-63. DOI:10.2165/11598990-000000000-00000 · 2.42 Impact Factor
Show more